TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Surgical Treatment of Rhino-Sinusal Mucormycosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman, over 18 years old, presenting a mucormycosis on a sinus biopsy showing large filaments with non or little septae compatible with a mucoral or with a positive culture for a mucoral on a sinus sample associated to clinical head \& neack anomalies (endoscopic) \& scans compatible with a mucormycosis previous to the inclusion and this whatever the patient incumbent pathology.~* Patient treated by liposomal amphotericin B or just before being treated~* Signature of informed consent :~  * by the patient if he is able to express their will~ * by the family or close, if the patient is unable to consent~* Inclusion in emergency clause is possible ( CPP agreement ) if the patient is incapacitated , no close is present and that the surgery is urgent~* Person affiliated to a Health Security System (beneficiary)~Exclusion Criteria:~* Pregnancy, breastfeeding~* Disseminated Mucormycosis (involvment of one site distant from the head and neck)~* Known hypersensitivity to a polyene~* Absence of documentation of mucormycosis (histological, mycological)~* Contraindication to the completion of the surgery as provided in this protocol~* Patient is the subject of a guardianship or tutelage measure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multiple Surgeries (Type: EXPERIMENTAL): Patients undergoing transnasal endoscopic surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Music Therapy Advocacy Recording Intervention (MTAR) on Internalized Stigma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the HMHCC ACU~* Able to read and comprehend the ISMI questionnaire, provide informed consent,~* With a severe mental illness of prolonged duration with a significant degree of disability or social dysfunction~Exclusion Criteria:~* Patients on S1 status (1:1 patient observation) or isolation protocol~* Evidence of organic brain disease, severe acute symptomatology, hearing deficit, and intellectual disability.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): The intervention consists of a sequence of five music therapy song-writing and recording groups, one per day. Internalized stigma will be assessed within 3 days of admission (pretest/baseline), at ten days (posttest), and at 3 weeks from baseline (follow-up), using the Internalized Stigma of Mental Illness Inventory.
- Control Group (Type: NO_INTERVENTION): Access to standard of care services that include several groups per day focused on topics of coping skills, mindfulness, journaling, creative arts, wellness recovery, recreation, and at least one music therapy group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Control of Major Bleeding After Trauma Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>=18 years~* Acutely injured~* SBP\<70 mmHg or SBP 71-90 mmHg with heart rate (HR)\>108 beats per minute.~Exclusion Criteria:~* Visibly or verbally reported pregnant women~* known prisoners~* unsalvageable injuries (defined as asystolic or cardiopulmonary resuscitation prior to randomization)~* known objection to blood products~* the patient has an opt-out bracelet or, necklace or wallet card~* a family member present at the scene objects to the patient's enrollment in research.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plasma (Type: EXPERIMENTAL): If the patient is randomized to experimental arm, 2 units of frozen type AB plasma (FP24) will be thawed in the Plasmatherm Dry Thawing and Warming Device according to the operator manual as approved by the FDA in the ambulance and infusion will commence as soon as the type AB plasma is ready, and will continue during transport to the emergency department (ED). After infusion of 2 units of type AB plasma is completed, subsequent care will proceed per institutional, Advanced Trauma Life Support (ATLS) guided resuscitation with acute packed red blood cells (pRBC) administration determined by the hemodynamic response and additional blood component administration guided by rapid thrombelastography (rTEG) and coagulation panel assessment in conjunction with clinical scenario.
- Standard (Type: ACTIVE_COMPARATOR): If the patient is randomized to the standard arm, the patient will be given intravenous crystalloid fluid (normal saline) as the initial resuscitation fluid with 2 large bore IVs based on the current ATLS guidelines, the standard of care. Subsequent care will proceed per institutional, ATLS guided resuscitation with acute packed red blood cells pRBC administration determined by the hemodynamic response and additional blood component administration guided by rTEG and coagulation panel assessment in conjunction with clinical scenario.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Patient's Satisfaction of Bispectral Index-guided Monitored Anesthesia Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving ear surgery with ASA physical status 1 or 2~Exclusion Criteria:~* Age under 19 years~* Pregnancy~* Cognitive disorder affecting daily activity~* Patients who cannot participate in the survey~* Allergy to the medication~* History of sedative abuse

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- OAA/S (Type: ACTIVE_COMPARATOR): The patients in the control group will receive MAC titrated according to observer's assessment of anesthesia/sedation(OAA/S) score.
- BIS (Type: ACTIVE_COMPARATOR): The patients in the control group will receive MAC titrated according to bispectral index(BIS).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hurler-Scheie,Scheie form of MPS I, of Hurler 2 years after hematopoietic stem cell transplantation~* Spinal cord compression~* Age greater than 8 years~* Able to provide legal informed consent~* Aware of clinical treatment option of observation without treatment or surgical decompression~* Negative urine pregnancy test at screening (non-sterile females of child-bearing potential only)~* Currently using two acceptable methods of birth control (non-sterile females of child-bearing potential who are sexually active only)~* Willing and able to comply with study procedures~Exclusion Criteria:~* Severe (Hurler) form of MPS I~* Desires surgical or medical treatment of spinal cord compression~* Spinal cord compression that warrants immediate surgical intervention~* Pregnancy or lactation~* Hematopoietic stem cell transplantation within 2 years of study enrollment~* Receipt of an investigational drug within 30 days of enrollment~* Infusion reactions to laronidase that required medical intervention, prophylaxis, or altered enzyme administration~* Significant anti-iduronidase antibody titer~* Recent initiation of intravenous laronidase (within past 6 months)~* Presence of cervical subluxation or similar external pathology as the major cause of cord compression symptoms for which surgical intervention should be immediately undertaken

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intrathecal laronidase (Type: EXPERIMENTAL): laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Femoral Neck Fracture System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Must be 18 years of age or older~2. Must provide written informed consent~3. Willing to make all required study visits for one year post-operation~4. Subject has experienced a displaced or non-displaced intracapsular femoral neck fracture and is scheduled for repair using the CONQUEST FN Femoral Neck Fracture System.~Exclusion Criteria:~1. Subject with known sensitivity or allergies to stainless steel~2. Subject with fracture occurring more than 7 days prior to surgery~3. Subject has more than one fracture on the hip requiring surgery~4. Subject is considered obese by a Body Mass Index \> 40 at the time of surgery~5. Therapy with another investigational agent within thirty 30 days of screening~6. Subject has emotional or neurological condition that precludes cooperation and compliance~7. Subject has undergone previous surgery on hip.~8. Subject has severe bow of the target hip or gross distortion of the femur.~9. Current systemic therapy with cytotoxic drugs~10. Subject has a physical condition that would preclude adequate implant support or impede healing (e.g. blood supply impairment, insufficient bone quality or quantity, or an active local or systemic infection).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control femoral neck fracture system (Type: OTHER): This is a single arm study of subjects who are to be implanted with the CONQUEST FN™Femoral Neck Fracture System for treatment of a trauma related femoral neck fracture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female volunteers, aged 18 years and above, with persistent asthma and allergic rhinitis~* On a minimum of 200μg BDP of Inhaled corticosteroid (ICS)~* FEV1 ≥ 60 % predicted~* Positive skin prick test, or record of elevated allergen-specific IgE to at least 1 perennial allergen~* Methacholine PC20 \< 8mg/ml at Visit 1~* Ability to give informed consent~Exclusion Criteria:~* Other respiratory diseases such as COPD, bronchiectasis or allergic bronchopulmonary aspergillosis (ABPA) which are considered to be significant in the opinion of the study physician Nasal polyps ≥ Grade 2~* An asthma exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 month of the study commencement, or 3 months if hospital admission was required~* Any clinically significant medical condition that may endanger the health or safety of the participant. For example: Patients who have tuberculosis or any type of untreated infection or have had recent surgical operation or injury to the nose or mouth.~* Participation in another trial within 30 days before the commencement of the study~* Pregnancy or lactation~* Unable to comply with the procedures of the protocol~* Unable or unwilling to consent~* Taking prohibited medications as listed in section 6.7.2 Prohibited Medications~* Hypersensitivity to the active substances or to any of the excipients of Dymista Nasal Spray.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azelastine-Fluticasone Nasal (Type: ACTIVE_COMPARATOR): 137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate per actuation. 1 squirt twice daily
- Placebos (Type: PLACEBO_COMPARATOR): contains the same components as Dymista nasal spray with the exception of the active ingredients. 1 squirt twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: StartRIGHT: A Pilot Research Study About Diabetes Diagnosis & Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recent clinical diagnosis of Diabetes (the working definition of recent will initially be within 3 months, but this may be modified if required).~* Aged 18 - 50 yrs of age at diagnosis.~* Able and willing to provide informed consent~Exclusion Criteria:~* Gestational diabetes~* Known secondary diabetes~* Unable/unwilling to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- ODS from enrolment (Type: EXPERIMENTAL): Optimised Diagnostic Strategy used from enrolment to study
- ODS at end of study (Type: NO_INTERVENTION): ODS fed back at the end of the participants involvement with the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be a candidate for a new arteriovenous graft~* Be either currently on dialysis or ready to begin dialysis as soon as the access device (AV graft with Hemoaccess Valve System) is ready for use.~* Be prepared to receive dialysis at dialysis centers in proximity of study centers~* Have an outflow vein of greater than or equal to 3mm in diameter to which the graft can be successfully anastomosed.~* Be able to communicate with study personnel.~* Be considered by the physician to be readily available for subsequent visits.~* Be willing to comply with all aspects of the treatment and evaluation as directed over the duration of the study.~* Allow representatives of the Sponsor, the designated Clinical Research Organization, the Institutional Review Board and the FDA to review his/her relevant medical records that pertain to this study.~Exclusion Criteria:~* An identification of a central venous stenosis on the ipsilateral side is documented or otherwise identified~* An identification of an arterial venous stenosis on the ipsilateral side is documented or otherwise identified~* A hypercoagulable state is documented or otherwise identified and/or previous AV access failures have occurred without an identifiable cause.~* Has a life expectancy of less than one year.~* An immunodeficiency syndrome~* An organ transplant is expected within 6 months of enrollment~* 3 or more previous new AV graft or fistula placements have occurred.~* Body habitus (e.g., extremely small or obese arms( precludes HVS device implantation or access.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemoaccess Valve System (Type: EXPERIMENTAL): Valve system for use with AV graft

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Medico-economic Study of the Lobo-isthmectomy Assisted Robot

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient candidate for thyroid lobectomy or lobo-isthmectomy for benign nodular disease~* normal laryngeal mobility (clinical evaluation by an ENT (Ear-Nose-Throat) Doctor)~* breast cancer absence being supported~* No suspected thyroid cancer~* Nodules size \<6cm~* Confirm Benin character nodules by fine needle biopsy made within 6 months prior to patient inclusion~* Patient available for post-operative follow-up of 12 months~Exclusion Criteria:~* Patient participating or having participated in another interventional study in the previous 3 months or exclusion period determined by a previous study~* Patient under guardianship or trusteeship or under judicial protection~* Inability to give informed patient information~* Pregnant women, breastfeeding or parturient~* Contraindications (or incompatible combination therapy) for a necessary treatment in this study~* contraindication to general anesthesia~* Emergencies~* Breast Cancer being supported~* treatment or surgical sentinel node of the planned breast cancer~* thyroid nodule ranked in the ultrasound TIRADS 5 (Thyroid image reporting and data system)~* Fine needle aspiration biopsy with BETHESDA score result 5 and 6~* Plunging Nodule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- lobo isthmectomy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NYHA II-IV Heart Failure~* Left ventricular ejection fraction \< 45%~* Stable heart failure medication~* eGFR by sMDRD formula between 30 and 60 mL/min/1.73m2~Exclusion Criteria:~* Known hypersensitivity to study drug or ACEi~* Concomitant treatment with both ARB and Aldosterone Receptor Antagonist~* Symptomatic Hypotension~* Acute Heart Failure~* History of stroke, acute coronary syndrome, PCI or angioplasty within past 3 months~* Serum potassium \> 5.2 mmol/L~* Right heart failure due to severe pulmonary disease~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Aliskiren (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a suspected or biopsy proven newly diagnosed GBM, or a recurrent GBM or suspected GBM (in patient with pathologically diagnosed prior World Health Organization \[WHO\] grade II or III tumor) in a patient undergoing a clinically-indicated surgery.~* Age \>= 18 years of age.~* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%)~* Life expectancy is not a consideration for protocol entry~* Patients must have normal organ and marrow function as defined below:~* Absolute neutrophil count \>= 1,500/uL~* Platelets \>= 100,000/uL~* Total bilirubin within normal institutional limits~* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal~* Creatinine within normal institutional limits; OR~* Creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal~* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately~* Ability to understand and the willingness to sign a written informed consent document or have a parent or guardian with the ability to understand and the willingness to sign a written informed consent~Exclusion Criteria:~* Prior therapy is not an exclusion criterion~* Patients may not be receiving any other investigational agents~* History of allergic reactions attributed to aminolevulinic acid (ALA)~* Current treatment with hypericin (or an extract) or other photosensitizing agents~* Personal or immediate family (parents, siblings, children) history of porphyrias~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ALA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (aminolevulinic acid) (Type: EXPERIMENTAL): Patients receive aminolevulinic acid PO 2-4 hours before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy